streptozocin + hydroxyurea + fluorouracil + mitomycin C

This is a combination chemotherapy regimen consisting of four antineoplastic agents: **streptozocin**, **hydroxyurea**, **fluorouracil**, and **mitomycin C**. Each component has a distinct mechanism of action: - **Streptozocin** is an alkylating agent, primarily used against pancreatic neuroendocrine tumors; it targets DNA, causing strand breaks and inhibition of synthesis. - **Hydroxyurea** is a ribonucleotide reductase inhibitor that blocks DNA synthesis by inhibiting conversion of ribonucleotides to deoxyribonucleotides. - **Fluorouracil (5-FU)** is a pyrimidine analog antimetabolite that inhibits thymidylate synthase and incorporates into RNA and DNA, disrupting their function and synthesis. - **Mitomycin C** is an alkylating agent that becomes active after enzymatic reduction and cross-links DNA, thereby inhibiting DNA synthesis. This regimen combines cytotoxic agents with non-overlapping mechanisms to increase antitumor activity. It is considered for advanced or metastatic malignancies, particularly in oncology protocols targeting gastrointestinal or pancreatic cancers, although the specific combination is uncommon and not associated with a unique brand name.